TickerTalks
Browse all tickers →
TickerTalks›$TLSA
TLTLSA

Tiziana Life Sciences Ltd

$TLSA·$65M·Biotechnology·Healthcare
$0.98-1.3%YTD-34.0%1Y-47.2%
Price updated 9h ago·X counts updated 8h ago
TLTLSA
$TLSATiziana Life Sciences Ltd
$0.98-1.31%32 posts0.9×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $TLSA on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

32X posts · last 7 days
Aug 27Sep 9
Chatter Meter
0.9×
QuietNormal · 1×Loud

How loud $TLSA's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-09-08

Tiziana appears on a healthcare-CEO-buying list where charts show bottoming process — 'many might be multi-baggers in the medium term' alongside KURA, PRE, PRCT, MLAB and BSX. One poster bought calls back 'because why not.'

Read what X is saying about $TLSA

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $TLSA — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-09-08

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Tiziana with BTIG initiation $7 PT — Phase 2a BANYAN ALS data pending at ALS Nexus 2026.

Tiziana Life Sciences is a nano-cap neuro-focused biotech — the specific way to trade the Treg-based approach to neurodegeneration and ALS. BTIG initiated coverage with a 12-month $7 PT, and Phase 2a BANYAN trial data is queued for presentation at ALS Nexus 2026.

Where the setup earns catalyst-play:

  • The financial base is deeply story-quality: essentially pre-revenue, ROIC -41%, and priced at a $70M market cap — Tiziana is spending on the neurodegeneration pipeline, and the current price is entirely optionality on the Treg-approach data landing positively.
  • The BTIG initiation is the specific institutional-catalyst: a Buy rating with $7 12-month PT (7x current) means at least one credible sell-side firm sees a specific commercial pathway, which pulls new capital in.
  • The Phase 2a BANYAN ALS Nexus 2026 presentation is the load-bearing data event: ALS trial readouts are binary catalyst events, and a positive presentation would immediately re-rate the equity.

The coil resolves on the ALS Nexus 2026 Phase 2a BANYAN data. Miss the specific efficacy signals and the tape drifts on burn; hit them and the sub-$2 setup with BTIG's $7 target becomes the multi-bagger. Traders 'buying calls, taking morning gains, rolling into other names' is honest tape read; the $360 pivot skeptic is honest tactical caveat.

Agrees with X sentimentAgree with the bull framing — the BTIG initiation with $7 PT, Phase 2a BANYAN pending at ALS Nexus 2026, and the trader-driven momentum setup are all real anchors. The $360 pivot skeptic is honest tactical caveat but doesn't invalidate the specific catalyst framing.

What to watch: Watch for ALS Nexus 2026 Phase 2a BANYAN data presentation content, any additional analyst initiation, and cash-runway disclosures. A positive BANYAN readout is the multi-bagger catalyst; a data miss is the specific reset trigger.

btig initiation 7 ptbanyan phase2a dataals nexus 2026

Read the AI verdict on $TLSA

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing nasal drug delivery of immunotherapy biologics for cancer and autoimmune disease.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $TLSA.

Biotechnology · Healthcare

GLP-1/obesity and gene-editing platforms continue to command premium multiples; mRNA therapeutics pipeline richness sustains broader biotech sentiment. FDA PDUFA catalysts and Phase-3 readouts are the near-term binary events across the cohort.

What this means for $TLSA

Neutral — Talis Biomedical; point-of-care diagnostics, binary.

Top industry ETF

$IBBiShares Biotechnology ETF
+22.2%YTD
+43.8%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-4.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-41.2%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
—
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-126%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 1, 2026$-0.22$-0.09-143.0%
Q3 2025Oct 3, 2025$-0.10$-0.07-35.4%
Q2 2025Jul 8, 2025$-0.06——
Q3 2024Oct 18, 2024$-0.18——
Next earningsFri, Sep 18·consensus EPS $-0.08

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q4 FY25$0———$-0.22$-6.0M
Q2 FY25$0———$-0.10$-6.8M
Q4 FY24$0———$-0.13$-1.5M
Q2 FY24$0———$-0.18$305K

Forward consensus

5-year forecast · up to 1 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$0$0 – $0-$0.17-$0.17 – -$0.170
FY27$0$0 – $0-$0.18-$0.18 – -$0.180
FY28$0$0 – $0-$0.19-$0.19 – -$0.190
FY29$0$0 – $0-$0.19-$0.19 – -$0.190
FY30$97.4M$97.4M – $97.4M-$1.29-$1.29 – -$1.291

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.3×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.7%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-8.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-26.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 31.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.465-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyAug 5Ivor ElrifiCEO237.6K sh$238KBuyAug 4Ivor ElrifiCEO83.8K sh$81KBuyAug 3Ivor ElrifiCEO667.0K sh$667KBuyJul 21Gabriele M CerroneDirector42.4K sh$42KBuyJun 12Gabriele M CerroneDirector15.0K sh$17K
+ 2 other (2 awards) in window

See when $TLSA insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsJul 233
AI summary

Ivor Elrifi, CEO and Director of Tiziana Life Sciences Ltd (TLSA; London, UK), filed an initial Form 3 reporting direct beneficial ownership of 3,805,261 shares of TLSA common stock, effective March 18, 2026 (filed later). This substantial insider stake by the CEO of the UK-based clinical-stage biopharmaceutical company signals meaningful alignment between leadership and shareholders, though the Form 3 itself carries no operational news.

3New insider — initial holdingsMay 223
3New insider — initial holdingsMar 183
+ 16 other (14 6-Ks · 1 20-F · 1 NT 20-F) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegenerationproactiveinvestors.com·7d agoDow climbs as stocks rebound on earnings, falling Treasury yieldsproactiveinvestors.com·7d agoTiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026proactiveinvestors.com·17d agoTiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026globenewswire.com·17d agoGemini Pro delay leaves Google with an empty flagship tierproactiveinvestors.com·17d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$AURA$ALT$MRNA$NWBO$RARE$IBRX$SLS$ABCL
Voices on X · top 3 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport